Table 3. Characteristics Associated With All-Cause Mortality in People Experiencing Homelessness Who Engaged in an OBAT Program.
Patient characteristic | Adjusted hazard ratio (95% CI) | P value |
---|---|---|
Sociodemographic characteristics | ||
Age (per 10-y increment) | 1.34 (1.16-1.54) | <.001 |
Sex | ||
Female | 1 [Reference] | [Reference] |
Male | 0.99 (0.71-1.38) | .96 |
Race/ethnicity | ||
White | 1 [Reference] | [Reference] |
Non-Hispanic Black | 0.67 (0.43-1.06) | .08 |
Hispanic | 0.73 (0.52-1.03) | .07 |
Other/unknown | 0.78 (0.42-1.47) | .45 |
Housing status | ||
Othera | 1 [Reference] | [Reference] |
Shelter/street | 0.73 (0.54-0.98) | .03 |
Clinical characteristics | ||
Charlson comorbidity index | ||
0-1 | 1 [Reference] | [Reference] |
≥2 | 1.55 (1.10-2.18) | .001 |
Alcohol use disorder | 1.23 (0.85-1.77) | .27 |
Other drug use disorder | 0.92 (0.63-1.34) | .65 |
Serious mental illnessb | 0.86 (0.55-1.35) | .51 |
Medication prescriptionsc | ||
Benzodiazepine | 0.66 (0.20-2.14) | .49 |
Opioidd | 0.64 (0.16-2.60) | .53 |
Antidepressant | 0.49 (0.23-1.08) | .08 |
Antipsychotic | 0.93 (0.32-2.66) | .89 |
Other sedating medicationse | 1.05 (0.32-3.47) | .94 |
Naloxone | 1.19 (0.29-4.95) | .81 |
Addiction treatment–related characteristics | ||
Year of first OBAT encounter | ||
2008-2013 | 1 [Reference] | [Reference] |
2014-2018 | 1.27 (0.90-1.79) | .17 |
Site of first OBAT encounter | ||
Clinic | 1 [Reference] | [Reference] |
Shelter/outreach | 0.58 (0.36-0.93) | .03 |
OBAT attendancec | ||
Out of care | 1 [Reference] | [Reference] |
In care | 0.34 (0.21-0.55) | <.001 |
Abbreviation: OBAT, office-based addiction treatment.
Includes assisted living facility, doubled up, housing with and without supportive services, motel, respite home, residential treatment center, skilled nursing facility, transitional housing, other housing status, and unknown housing status.
Includes a diagnosis of bipolar disorder and/or schizophrenia.
Time-varying, measured on a monthly basis.
Excludes buprenorphine.
Includes nonbenzodiazepine sedative-hypnotics and trazodone.